Have any questions? 706-721-6582 or cts@augusta.edu
- TL-895-202: A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 with Standard Available Treatment versus Standard Available Treatment for the Treatment of COVID-19 in Patients with Cancer
Clinical Trial
TL-895-202: A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 with Standard Available Treatment versus Standard Available Treatment for the Treatment of COVID-19 in Patients with Cancer
Patients are being asked to take part in this study because they were admitted to the hospital, have COVID-19 and cancer. Our site will participate in both Part 1 and Part 2. Part 1 is being done to find the TL-895 dose to be tested in Part 2. Participants in Part 1 will take TL-895. Part 2 will start after Part 1 is done. Participants in Part 2 will be randomly assigned to take TL-895 or placebo (pill that contains no medicine). Randomly assigned is like the flip of a coin. The study doctor, Sponsor, and you will not know if you are taking TL-895 or placebo.
Eligibility Criteria
- Male or female, aged 18 years or older Known diagnosis of active cancer that is not considered cured or disease free. Confirmed COVID-19 infection Ability to swallow and absorb oral medications
RESEARCH. INNOVATION. DISCOVERY.